C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease

C2N Diagnostics and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are partnering to investigate the connections between Parkinson’s disease, Alzheimer’s disease, and related neurodegenerative disorders. With more than $1.5 million in funding from MJFF, researchers will identify and measure blood biomarkers to explore the overlap of these diseases, focusing on proteins like amyloid-beta and tau, which are central to Alzheimer’s, and alpha-synuclein, which is implicated in Parkinson’s and related conditions like Lewy body dementia and REM sleep behavior disorder. A key part of this collaboration involves the use of C2N’s PrecivityAD2 test to measure abnormal amyloid-beta and tau proteins in biosamples from over 2,000 participants in MJFF’s Parkinson’s Progression Markers Initiative (PPMI). This initiative aims to uncover biomarkers that accelerate progress in diagnosing, treating, and preventing Parkinson’s. The researchers will also deploy tests for the microtubule-binding region of tau, specific to tau tangles found in Alzheimer’s, to track disease progression and explore their role in Parkinson’s and other neurodegenerative diseases. This partnership highlights C2N’s expertise in precision diagnostics and its application beyond Alzheimer’s research. By analyzing how dementia-related biomarkers evolve over time, the study seeks to deepen understanding of disease mechanisms and support clinical trials for treatments targeting these intertwined conditions. Researchers aim to identify diagnostic tools and therapeutic strategies to benefit individuals living with Parkinson’s and other neurodegenerative diseases.